Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Xilio Therapeutics Inc (XLO)

Xilio Therapeutics Inc (XLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2 GlobeNewswire - Fri Apr 17, 3:01PM CDT

XTX601 demonstrated protease-dependent, tumor-selective activation and potent anti-tumor activity in multiple preclinical models  Consistent with Xilio’s clinically-validated masking technology,...

XLO : 8.51 (+2.28%)
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors GlobeNewswire - Thu Apr 16, 6:30AM CDT

WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...

ANIK : 14.33 (-3.50%)
XLO : 8.51 (+2.28%)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Fri Apr 3, 3:30PM CDT

WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...

XLO : 8.51 (+2.28%)
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results GlobeNewswire - Mon Mar 23, 6:30AM CDT

XTX501, a potential best-in-class bispecific PD-1 / masked IL-2, on track for planned IND submission in mid-2026 and Phase 1 initiation in the second half of 2026 Advancing potential first-in-class...

XLO : 8.51 (+2.28%)
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire - Tue Mar 17, 3:45PM CDT

WALTHAM, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...

XLO : 8.51 (+2.28%)
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split GlobeNewswire - Thu Mar 12, 7:30AM CDT

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...

XLO : 8.51 (+2.28%)
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference GlobeNewswire - Mon Mar 2, 7:00AM CST

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...

XLO : 8.51 (+2.28%)
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire - Mon Mar 2, 6:30AM CST

WALTHAM, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies...

XLO : 8.51 (+2.28%)
Xilio Therapeutics Announces Pricing of Underwritten Offering GlobeNewswire - Wed Feb 11, 8:34PM CST

WALTHAM, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing masked immuno-oncology therapies for people...

XLO : 8.51 (+2.28%)
Xilio Therapeutics Highlights Upcoming Milestones and Recent Corporate Updates GlobeNewswire - Thu Jan 8, 7:30AM CST

Received $35.8 million in gross proceeds from Series B warrant exercises, including full exercise by Coastlands Capital, Frazier Life Sciences and Gilead Sciences, Inc., and extended anticipated cash runway...

XLO : 8.51 (+2.28%)

Barchart Exclusives

How Sweet Is Sugar to Long-Term Investors? Barchart - 2 minutes ago
Sugar seems to be the hot commodity at this time. Does it have the market structure to interest long-term investment interests? Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.